Ann: Becoming a substantial holder, page-27

First 27 Last

Share
Profile

Follow
Uranman

217 Posts.

41

03/09/21

18:27

Post #: 55821370
Share

Originally posted by andrewasdf: ↑

I'm in a similar boat. I sold just under 11c but shifted proceeds immediately into other U names because I didn't want to miss on the action that was about to arrive from Sprott's ATM. So this has spared me from any FOMO.

Here's why I sold: my thesis was based on the ability of Mike Young to bring an asset into production. With Mike gone, that thesis was gone. The disappearance of Julian Tapp has confirmed my decision—he was the one with the permitting know-how and family connections.

Why is the stock rocketing? I'm not convinced it's related to an impending takeover. Would seem to be too expensive. John Borshoff left it about a year too late to do his M&A, IMO. U prices have now got away from him. More likely the reason stock price is going up is because VMY is one of the smallest stocks held by URA and URNM. So as money pours into this funds there is indiscriminate buying. If things have gone pear shaped at VMY then their timing couldn't be more perfect... the rising tide will ensure the Vimy boat gets lifted even with bad news.

In the short to medium term I expect that Mulga rock won't go ahead, but rising U prices will mean that Vimy holders do OK anyway as just a NT explorer. Maybe will get taken over once bad Mulga news comes out and SP drops a little.

Of course I could be completely wrong, but I'm happy to enjoy my U gains elsewhere for now. Good luck to all who are sticking around.

Expand

Thanks for the wishes, Andrew, and glad to see another Andrew buying big this week.

His 6% shareholding will soon be worth double or triple what he's invested to date.

Relative to its peers, anything below 25cts/sh for VMY stock is a bargain.

VMY Price at posting: 16.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HAS

Hastings progressing Yangibana to production with lower costs

The iron ore comeback: Can it last?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%